Business Strategy
The business model of 4SC is based on the discovery, development and validation of novel drug candidates until attractive partnering deals can be completed with international biotech and pharmaceutical companies. Subsequent development and commercialisation will be completed with these partners in return for upfront and milestone payments plus royalties. The resultant proceeds will generate continuous revenue for 4SC and its shareholders.
It is the strategy to establish a broad, value-generating pipeline with an attractive risk-reward profile with moderate research and development costs. Through its product portfolio 4SC addresses the pharmaceutical industry’s need for novel, innovative drug candidates to address patent expirations.
4SC is focused on small-molecules for autoimmune and cancer indications as these two disease areas offer high sales potential for the pharma industry, due to:
• Increasing patient numbers due to demographic trends
• High unmet need for new therapeutic approaches
• Insufficient treatment options, particularly in the oncology field
• Oral administration of small molecules delivers advantages for patients and healthcare economics
The execution of R&D projects is designed to ensure the long-term growth of 4SC through sustainable, operational income through:
• A risk-diversified pipeline comprising various, in parallel advancing clinical trials
• Different mechanisms of action and approaches for disease treatment and the synergistic use of expertise in proprietary drug development
• Efficient allocation of financial resources to R&D programmes